The behavioral working group of the Huntington Study Group and the European Huntington's Disease Network published comprehensive guidelines for managing behavioral symptoms in HD in 2018. These guidelines reflect expert consensus, as no large randomized trials exist specifically targeting behavioral symptoms, highlighting the need for ongoing research and updates.
Cognitive symptoms in HD remain a crucial aspect needing intervention. Clinical options are limited, but the focus of recent trials on cognitive symptoms marks significant progress. Sage Therapeutics is conducting studies examining their NMDA modulator as a potential treatment for cognitive impairment in HD.
With more resources available for symptomatic care and end-of-life care, educating families and caregivers about effective management strategies—whether at home or in clinical settings—is becoming increasingly important.
At the CHDI Foundation's annual therapeutic conference, the role of increasing CAG (cytosine-adenine-guanine) repeats in somatic tissues was highlighted, suggesting a deeper genetic understanding of Huntington's Disease progression.
#huntington-disease #cognitive-impairment #behavioral-symptoms #treatment-guidelines #genetic-factors
Collection
[
|
...
]